Results 31 to 40 of about 40,837 (237)

Angiotensin II Receptor Blocker Associated With Less Outcome Risk in Patients With Acute Kidney Disease

Frontiers in Pharmacology, 2022
Objective: The aim of this study was to explore the respective use of angiotensin-converting-enzyme inhibitors (ACEis) or angiotensin receptor blockers (ARBs) on the outcomes of patients who could be weaned from dialysis-requiring acute kidney injury ...
Vin-Cent Wu, Yu-Feng Lin, Nai-Chi Teng, Shao-Yu Yang, Nai-Kuan Chou, Chun-Hao Tsao, Yung-Ming Chen, Jeff S Chueh, Jeff S Chueh, Likwang Chen   +9 more
doaj   +1 more source

Cardiovascular and neuropsychiatric outcomes with PCSK9 inhibitors in atherosclerotic cardiovascular disease: A retrospective cohort study

British Journal of Clinical Pharmacology, EarlyView.
Study design and main findings. After 1:1 propensity score matching, 60 885 PCSK9 inhibitor users and 60 885 statin‐only users with ASCVD were compared. Kaplan–Meier curves show 12‐month cumulative event‐free survival for MACE, psychiatric disease, and neurodegenerative disease.
Tianshu Gu, Yang Chen, Nan Zhang, Uazman Alam, Riccardo Proietti, Tong Liu, Kang‐Yin Chen, Gregory Y. H. Lip   +7 more
wiley   +1 more source

Platelet FcɣRIIa Expression Refines Clinical Risk Assessment After Myocardial Infarction

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background In patients with myocardial infarction (MI), quantifying expression of platelet FcɣRIIa (pFCG) stratifies risk of subsequent MI, stroke, and death. Aims Assess the prognostic implications of clinical risk alone and in combination with the pFCG test.
David J. Schneider, Sean R. McMahon, Dominick J. Angiolillo, Alexander C. Fanaroff, Homam Ibrahim, Patrick K. Hohl, Brett L. Wanamaker, Mark B. Effron, Peter M. DiBattiste, behalf of the investigators   +9 more
wiley   +1 more source

The High‐Sensitivity C‐Reactive Protein−Albumin−Lymphocyte Index Is a Prognostic Marker for All‐Cause and Cardiovascular Mortality in Patients With ST‐Elevation Myocardial Infarction

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Inflammation and immune dysfunction may worsen the prognosis of patients with ST‐segment elevation myocardial infarction (STEMI). Aims This study aimed to assess whether the high‐sensitivity C‐reactive protein–albumin–lymphocyte index (hsCALLYI) could be used to predict the prognosis of STEMI patients who received emergency ...
Xinuo Ma, Wei Zhang, Ningli Zhang, Qinghua Zhong, Tao Shi, Sirui Yang, Fazhi Yang, Yujuan Peng, Lixing Chen   +8 more
wiley   +1 more source

Risk factors for angiotensin converting enzyme inhibitor angioedema in a South African population

Frontiers in Allergy
IntroductionAngiotensin converting enzyme inhibitors (ACEI) have proven mortality and morbidity benefit in hypertension, ischemic heart disease, heart failure, and renal disease and are among the most prescribed medications globally.
Cascia Day, Cascia Day, Lovemore Mapahla, Lovemore Mapahla, Melissa Ribeiro, Mimi Deetlefs, Cathryn McDougall, Adelein Engelbrecht, Erika Jones, Sarah Pedretti, Jonny Peter, Jonny Peter   +11 more
doaj   +1 more source

Renoprotective Effect of the Combination of Renin-angiotensin System Inhibitor and Calcium Channel Blocker in Patients with Hypertension and Chronic Kidney Disease

Chinese Medical Journal, 2016
Background: Renin-angiotensin system inhibitor and calcium channel blocker (CCB) are widely used in controlling blood pressure (BP) in patients with chronic kidney disease (CKD).
Rong-Shuang Huang, Yi-Ming Cheng, Xiao-Xi Zeng, Sehee Kim, Ping Fu   +4 more
doaj   +1 more source

Impact of a “Chart Closure” Hard Stop Alert on Prescribing for Elevated Blood Pressures Among Patients With Diabetes: Quasi-Experimental Study

JMIR Medical Informatics, 2020
BackgroundUniversity of California at Los Angeles Health implemented a Best Practice Advisory (BPA) alert for the initiation of an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin-receptor blocker (ARB) for individuals with diabetes. The BPA
Ramirez, Magaly, Chen, Kimberly, Follett, Robert W, Mangione, Carol M, Moreno, Gerardo, Bell, Douglas S   +5 more
doaj   +1 more source

Evaluation of Treatment Response of Calcified Nodules and Nodular Calcified Lesions Using Mean Density on Coronary Computed Tomography Angiography

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Calcified nodules (CN) and nodular calcifications (NC) present significant challenges during percutaneous coronary intervention (PCI) because of their protruding morphology and high rigidity, which often result in inadequate stent expansion and suboptimal procedural outcomes.
Akito Setoguchi, Keita Iyama, Ryosuke Iwasaki, Saburo Kusumoto, Yoshiyuki Doi, Tatsuya Nunohiro, Masayoshi Takeno, Koji Maemura   +7 more
wiley   +1 more source

Angiotensin-converting enzyme inhibitor-induced angioedema: Proposal for a diagnostic score

World Allergy Organization Journal
Objective: Angiotensin-converting enzyme inhibitor (ACEI)-induced angioedema (AE-ACEI) may be life-threatening, and the treatment should therefore be discontinued.
Alexis Bocquet, MD, Nicolas Marmion, MD, Isabelle Boccon-Gibod, MD, Laurence Bouillet, MD, PhD   +3 more
doaj   +1 more source

Clinical outcomes following discontinuation of renin-angiotensin-system inhibitors in patients with type 2 diabetes and advanced chronic kidney disease: A prospective cohort studyResearch in context

EClinicalMedicine, 2023
Summary: Background: Renin-angiotensin-system inhibitors (RASi), that include angiotensin converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) reduce proteinuria, delay chronic kidney disease (CKD) progression, protect against ...
Aimin Yang, Mai Shi, Eric S.H. Lau, Hongjiang Wu, Xinge Zhang, Baoqi Fan, Alice P.S. Kong, Andrea O.Y. Luk, Ronald C.W. Ma, Juliana C.N. Chan, Elaine Chow   +10 more
doaj   +1 more source